HRMY - CIK 0001802665
Harmony Biosciences Holdings, Inc. (HRMY) reported revenue of $868.45M for fiscal year 2025, as filed in its audited annual report with the SEC.
| Fiscal year | Revenue | Change |
|---|---|---|
| FY 2025 | $868.45M | +21.5% |
| FY 2024 | $714.73M | +22.8% |
| FY 2023 | $582.02M | +32.9% |
| FY 2022 | $437.86M | +43.4% |
| FY 2021 | $305.44M | +91.2% |
| FY 2020 | $159.74M | +2564.6% |
| FY 2019 | $6.00M | - |
Harmony Biosciences Holdings, Inc. (HRMY) reported revenue of $868.45M for fiscal year 2025, as filed in its audited annual report with the SEC.
Between fiscal 2019 and fiscal 2025, Harmony Biosciences Holdings, Inc.'s revenue grew from $6.00M to $868.45M.
Data parsed from SEC EDGAR XBRL filings. See the full market cap rankings.